CORVUS PHARMACEUTICALS INC (CRVS)
Sector: Health Care
2026 Annual Meeting Analysis
CORVUS PHARMACEUTICALS INC · Meeting: June 11, 2026
Directors FOR
2
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Two Class I Directors with Terms to Expire at the 2029 Annual Meeting of Stockholders
Dr. Miller has served as CEO and director since 2014 and the company's 3-year stock return of +1,431% vastly outpaces XBI (the SPDR S&P Biotech ETF), which returned +67.5% over the same period — a gap of +1,364 percentage points, far exceeding the 65-point threshold required to trigger a concern, meaning shareholders have been very well rewarded during his tenure; no overboarding, attendance, independence, or other governance issues were identified.
Dr. Grais has served as a director since January 2019 and brings strong relevant experience as a former biotech CEO, venture capital managing member, and attorney; the company's stock has dramatically outperformed XBI (the SPDR S&P Biotech ETF) during her tenure, she holds only one other public company board seat (ICON plc), and all attendance and independence requirements are met.
Both Class I nominees — CEO Dr. Miller and independent director Dr. Grais — pass all policy screens. The company's extraordinary 3-year stock performance of +1,431% versus XBI's +67.5% eliminates any TSR concern, and neither nominee triggers overboarding, attendance, or independence flags.
Say on Pay
✓ FORCEO
Richard A. Miller, M.D.
Total Comp
$7,031,566
Prior Support
N/A
CEO Dr. Miller's total reported compensation of approximately $7.0 million for 2025 consists almost entirely of stock option awards (about $6.99 million out of $7.03 million total), with a base salary of only $36,566 — this is an unusually low fixed salary reflecting a deliberate cash conservation strategy, and the overwhelming majority of pay is variable and tied to stock price performance. The company's stock returned +1,431% over the past three years compared to +67.5% for XBI (the SPDR S&P Biotech ETF), demonstrating exceptional alignment between executive pay and shareholder outcomes. The company also has a compliant clawback policy in place, no bonus was awarded for 2025, and no prior Say on Pay vote results were identified that would require a response.
Auditor Ratification
✓ FORAuditor
PricewaterhouseCoopers LLP
Tenure
12 yrs
Audit Fees
$947,000
Non-Audit Fees
$2,000
PricewaterhouseCoopers has audited Corvus since fiscal year 2014 (approximately 12 years), which is well below the 25-year tenure threshold that would raise independence concerns; non-audit fees of $2,000 represent just 0.2% of audit fees of $947,000, far below the 50% ratio that would trigger a negative vote; and PwC is a Big 4 firm fully appropriate for a company of this size and complexity.
Overall Assessment
The 2026 Corvus Pharmaceuticals annual meeting presents three straightforward proposals — director elections, auditor ratification, and executive compensation — all of which warrant a FOR vote. The company's outstanding stock performance (up more than 1,400% over three years versus the biotech benchmark XBI's 68%), a nearly all-variable executive pay structure, a clean auditor fee profile, and qualified director nominees with no governance red flags support affirmative votes across the entire ballot.